Sustained-Release Naltrexone Formulation for Adverse Effect Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The co-administration of immediate-release naltrexone with bupropion or fluoxetine results in an unexpectedly high incidence of adverse effects, which is significantly higher than expected from their separate administration, posing a challenge in managing weight-related conditions effectively.
Innovation Solution
Development of a sustained-release naltrexone formulation that reduces adverse effects associated with the co-administration of naltrexone and monoamine reuptake inhibitors like bupropion or fluoxetine, by controlling the plasma concentration profile to achieve a naltrexone C max and AUC that is 80% or less of immediate-release naltrexone, and a 6-beta naltrexol profile within 80% to 125% of immediate-release levels, using carriers such as hydroxypropylmethyl cellulose or polyethylene oxide to extend the release rate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immediate-release naltrexone is co-administered with bupropion or fluoxetine, then therapeutic effects are achieved, but adverse effects increase significantly
Solution Approach 1:
The patent divides the immediate-release naltrexone into a sustained-release formulation that releases the drug over time, segmenting the peak concentration into lower, prolonged concentrations. This segmentation of the concentration profile maintains therapeutic efficacy while reducing the harmful interaction peak with monoamine reuptake inhibitors
Solution Approach 2:
The patent transforms the static immediate-release formulation into a dynamic sustained-release formulation where the drug concentration changes over time. This dynamic release profile adapts to maintain therapeutic levels while avoiding the harmful concentration peaks that occur with immediate release
2Speed
If immediate-release naltrexone is used, then rapid onset of action is achieved, but adverse effects are more severe and prolonged
Solution Approach 1:
The sustained-release formulation creates a periodic action pattern where naltrexone is released continuously at controlled rates, replacing the single rapid peak with multiple lower concentration exposures over time. This periodic release maintains therapeutic effect while reducing adverse effect severity and duration
3Duration of action of stationary object
If higher doses of naltrexone are administered, then blockade duration is extended, but adverse effects increase in severity
Solution Approach 1:
The patent changes the concentration-time parameters of naltrexone administration by using sustained-release technology. Instead of high peak concentrations achieved through higher immediate doses, the formulation achieves prolonged blockade through lower, sustained concentrations, thereby extending duration without increasing adverse effect severity
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.